Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 2.62% to $89.76 on Monday, outperforming the broader market. This marked the stock's second consecutive day of gains, occurring on a positive trading day for both the S&P 500 Index and the Dow Jones Industrial Average.
Evercore ISI Adjusts Price Target on Zimmer Biomet to $110 From $120
Evercore ISI has adjusted its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $110, down from $120. This announcement was made on July 6, 2026. The company is a medical device maker specializing in orthopedic reconstruction implants and traumatology products.
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating the Potential 12.84% Upside in the Healthcare Sector
Zimmer Biomet Holdings, Inc. (ZBH) is a medical devices company with a market capitalization of $16.92 billion and a current stock price of $87.47. The company shows robust revenue growth, a moderate return on equity, and substantial free cash flow, with a potential upside of 12.84% based on analyst ratings. ZBH also focuses on strategic innovations like the ROSA Robot and ZBEdge Platform to maintain its market position in the evolving healthcare sector.
Smith & Nephew plc highlights its surgical technology portfolio as a global medtech player
Smith & Nephew plc is a global medical technology company specializing in orthopedics, sports medicine, and advanced wound management. The company's diverse portfolio includes products for joint replacement, trauma treatment, and chronic wound care, catering to an international market influenced by aging populations and increasing healthcare demands. This article details the company's business areas, global operations, and commitment to innovation and quality standards.
Enterprise value to revenue forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH
The article focuses on the enterprise value to revenue forward for Zimmer Biomet Holdings, Inc. (NYSE: ZBH), as presented on TradingView. It appears to be a financial data point or a section within a larger financial analysis platform.
Zimmer Biomet (ZBH) Stock Looks Cheap On Earnings But Faces Growth Doubts
Zimmer Biomet Holdings (ZBH) stock appears undervalued based on earnings multiples, trading below its industry average and Simply Wall St’s fair P/E estimate, despite a 40.9% decline in share price over five years. The company's valuation depends on whether its core business and the planned acquisition of Pacira BioSciences' iovera device can sustain earnings growth, potentially leading to a re-rating against peers. Investors need to consider if the current lower multiple reflects temporary caution or a lasting concern about execution and integration risks.
Zimmer Biomet (ZBH) director awarded 389 Phantom Stock Units in deferred pay plan
Zimmer Biomet Holdings, Inc. director Maria Teresa Hilado was granted 389.498 Phantom Stock Units under the company's Deferred Compensation Plan for Non-Employee Directors. These units track the value of Zimmer Biomet common stock and will be settled in cash in ten annual installments after her directorship ends, bringing her total holdings to 12,983.867 units. This transaction, filed on Form 4, is a compensation-related acquisition and does not involve open-market trades of actual common shares.
[Form 4] ZIMMER BIOMET HOLDINGS, INC. Insider Trading Activity
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of 180.323 phantom stock units as part of his board compensation, increasing his total to 2,990.182 units. These phantom units are tied to Zimmer Biomet common stock and will be settled in shares within sixty days after his directorship ends. The transaction was reported as neutral in impact and sentiment.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 3.92% to $87.47 on Thursday, outperforming competitors on a mixed trading day. This gain ended a three-day losing streak for the stock. The S&P 500 Index remained mostly unchanged, while the Dow Jones Industrial Average saw a 1.14% increase.
Zimmer Biomet (ZBH) director granted 317.369 cash-settled phantom stock units
Zimmer Biomet Holdings director Robert Hagemann was granted 317.369 cash-settled Phantom Stock Units as part of the company's Deferred Compensation Plan for Non-Employee Directors. These units are equivalent to shares of common stock on a 1-for-1 basis and are settled in cash, not actual shares. After this award, Hagemann now holds a total of 33,269.443 Phantom Stock Units, which will be paid out in five annual installments after his directorship ends.
Zimmer Biomet (ZBH) director awarded 317.369 phantom stock units in cash-settled plan
Arthur J. Higgins, a director at Zimmer Biomet Holdings, Inc. (ZBH), was awarded 317.369 phantom stock units through the company's Deferred Compensation Plan for Non-Employee Directors. These units are linked to common stock but will be settled in cash in ten annual installments after his service as a director ends. Following this award, Higgins now holds a total of 37,674.691 phantom stock units.
Zimmer Biomet (NYSE: ZBH) director receives cash-settled phantom stock grant
Michael J. Farrell, a director at Zimmer Biomet (NYSE: ZBH), received a grant of 432.776 cash-settled phantom stock units on June 30, 2026, as reported in a recent Form 4 filing. These units are part of the company's Deferred Compensation Plan for Non-Employee Directors and are valued 1-for-1 with common stock, to be settled in cash after his board service concludes. Following this grant, Farrell's total holdings amount to 19,606.716 phantom stock units, indicating routine compensation rather than open-market trading.
COO - Cooper Companies Inc Options
This article provides a detailed financial overview of Cooper Companies Inc (COO), including its last close price, various financial ratios, performance metrics, and insider/institutional ownership data. It lists key financial figures such as market cap, income, sales, P/E ratio, and EPS, alongside stock performance over different periods and analyst recommendations.
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Compass Therapeutics (CMPX) and 10x Genomics (TXG)
Healthcare companies Zimmer Biomet Holdings (ZBH), Compass Therapeutics (CMPX), and 10x Genomics (TXG) have received analyst coverage. Caitlin Roberts from Canaccord Genuity maintained a Hold rating on ZBH with an $83.00 price target, while John Newman of Canaccord Genuity maintained a Buy rating on CMPX with a $7.00 price target. David Westenberg from Piper Sandler assigned a Hold rating to TXG with a $42.00 price target.
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India
Medical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its new technology center in Bengaluru, India. The hires will focus on software engineering, product design, research and development, and support functions, with a significant emphasis on artificial intelligence applications. This expansion aligns with India's growing role as a hub for global capability centers in the healthcare industry.
Enterprise value to EBIT forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH
This article provides financial data for Zimmer Biomet Holdings, Inc. (NYSE: ZBH), focusing on its enterprise value to EBIT forward metric. The content appears to be a financial snapshot from a trading platform, displaying key financial information for the company. It serves as a data point for investors interested in ZBH's valuation.
Zimmer Biomet Holdings | SD: Specialized disclosure report
This report from moomoo provides a specialized disclosure regarding Zimmer Biomet Holdings (ZBH). It notes the stock's performance with a +1.51% change and includes links to associated documents. The content emphasizes that the information is for educational purposes only and does not constitute investment advice.
How Investors Are Reacting To Enovis (ENOV) Russell 2000 Defensive Index Removal And Rebalancing
Enovis Corporation (NYSE: ENOV) was removed from the Russell 2000 Defensive and Value-Defensive Indices on June 27, 2026, which may lead to short-term trading volatility as index-tracking funds rebalance. The article notes that this removal does not change Enovis's core strategy of margin improvement and integrating acquisitions, with the company reaffirming its 2026 revenue guidance. Despite current net losses and a goodwill impairment, Enovis projects significant revenue and earnings growth by 2029, suggesting a potential undervaluation based on analyst forecasts.
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. (ZBH) fell by 2.23% to $84.17 on Wednesday, experiencing its third consecutive day of losses. This underperformance occurred during a general market downturn, with the S&P 500 Index and Dow Jones Industrial Average also recording losses. The stock's decline suggests it fared worse than its competitors in the challenging market conditions.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, expanding access to non-opioid postsurgical pain management for approximately 40 million covered lives. This move, following similar policies from other major payers and the NOPAIN Act, aims to remove financial barriers and support clinician-led decisions for pain management. Pacira emphasizes its commitment to collaborating with healthcare stakeholders to advance non-opioid pain therapy access and value.
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
Pacira BioSciences is divesting its iovera medical device franchise to Zimmer Biomet for up to $140 million, including $70 million upfront and potential milestone payments. This move aligns with Pacira's strategy to focus on biopharmaceutical products and strengthen its balance sheet, while Zimmer Biomet expands its pain management portfolio. The iovera system is an FDA-cleared cryoneurolysis device for temporary pain relief.
Nnamdi Njoku appointed President of Omnicell (OMCL) while Randall Lipps remains CEO
Omnicell, Inc. has appointed Nnamdi Njoku as President, effective July 1, 2026, where he will also continue in his role as Chief Operating Officer. Randall A. Lipps will step down from the President role but will remain Chief Executive Officer and Chairman of the Board, with no changes to his compensation. Njoku will focus on Omnicell's long-term growth strategy, global operations scaling, and product innovation, including initiatives like the Omnicell Titan XT system and the OmniSphere platform.
Zimmer Biomet to acquire iovera device from Pacira for $140m
Zimmer Biomet has announced an agreement to acquire Pacira BioSciences' iovera drug-free medical device for up to $140 million. The deal includes an upfront payment of $70 million and potential future milestone payments. The iovera system uses focused cold therapy to alleviate pain, and the acquisition aims to expand its global reach.
La-Z-Boy VP Richmond sells $544,533 in common shares
LA-Z-BOY INC's VP Richmond Raphaell Z. sold 13,671 common shares for $544,533 after exercising employee stock options. The shares were sold at a weighted average price of $39.8313. Additionally, Mr. Richmond disposed of shares worth $37,878 to cover tax withholding obligations.
A Look at Zimmer Biomet Holdings Inc (ZBH) After 5.6% Decline -- GF Value $126.11 vs Price $86.09
Zimmer Biomet Holdings Inc (ZBH) shares recently dropped 5.6% to $86.09, which is 31.7% below its GF Value™ of $126.11, categorizing it as significantly undervalued. The company holds a GF Score™ of 76/100, indicating strong profitability and valuation, though financial strength and momentum are moderate. Insiders have sold $0.4 million in stock over the last three months with no buying activity, which could signal cautious sentiment.
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. (ZBH) fell by 5.64% on Tuesday, closing at $86.09, despite a generally positive trading session for the broader market. This marks the second consecutive day of losses for the stock. The S&P 500 Index and Dow Jones Industrial Average both saw gains on the same day.
American Financial Group stock hits 52-week low at $17.65
American Financial Group (AFGC) stock has dropped to a 52-week low of $17.65, marking a 7.46% decline over the past year. Despite this downturn, the company's financial health is rated "GOOD" by InvestingPro, and its P/E ratio suggests potential value for investors. The article highlights broader market pressures and company-specific challenges contributing to the stock's performance.
Stocks making the biggest moves midday: AeroVironment, Abivax, Astera Labs, Watts Water Technologies & more
This article details the biggest stock movements midday, including AeroVironment's rally due to strong earnings and revenue, Abivax's surge on positive ulcerative colitis treatment data, and Watts Water Technologies' jump after an analyst upgrade. Other companies like Astera Labs, Air Products and Chemicals, SolarEdge, Zimmer Biomet, Digital Realty Trust, Merck, AbbVie, and Sellas Life Sciences also saw significant price changes related to company-specific news or broader market trends.
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million.
Zimmer Biomet Holdings, Inc. has agreed to acquire the iovera° Business from Pacira BioSciences, Inc. for up to $140 million. The deal includes an upfront payment of $70 million and potential revenue-based milestone payments of an additional $70 million through December 31, 2031. This acquisition is anticipated to close in the third quarter of 2026, subject to customary closing conditions.
Maximus stock hits 52-week low at 53.35 USD
Maximus stock has fallen to a new 52-week low of $53.35, representing a 47% decrease from its high and a 36% drop over the last six months. Despite this significant downturn and broader market pressures, InvestingPro analysis suggests the stock might be undervalued, with a P/E ratio of 8.22 and a PEG ratio of 0.23. The company recently reported Q2 2026 EPS of $2.07, exceeding projections, and raised its guidance, indicating a positive outlook despite a revenue shortfall.
Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet
Pacira Biosciences has announced an agreement to divest its Iovera° business to Zimmer Biomet. This news was reported by Reuters and Refinitiv. The article provides a brief mention of the transaction, which is less than a minute read.
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome
Pacira BioSciences (PCRX) has announced the sale of its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. This strategic move aims to enhance Pacira's financial position and refocus resources on its core non-opioid pain management and regenerative health solutions. Despite a strong GF Score™ of 79/100, the company's high P/E ratio of 209.08x and recent insider selling of $1.0 million suggest investors should proceed with caution.
Pacira divests iovera device to Zimmer Biomet for up to $140m
Pacira BioSciences, Inc. has announced the sale of its iovera pain relief device to Zimmer Biomet Holdings, Inc. for up to $140 million. The deal includes an upfront payment and potential revenue-based milestone payments, with Pacira planning to use the net proceeds to strengthen its balance sheet. The transaction is expected to close in the third quarter of 2026.
Pacira BioSciences Divests CryoTech to Zimmer Biomet
Pacira BioSciences is selling its CryoTech business, including the iovera° device, to Zimmer Biomet for up to $140 million. This deal, expected to close in Q3 2026, will help Pacira reduce debt and pivot its focus further towards biopharmaceuticals. Approximately 66 Pacira employees will transfer to Zimmer Biomet as part of the agreement.
Pacira divests iovera device to Zimmer Biomet for up to $140m
Pacira BioSciences is selling its iovera pain relief device to Zimmer Biomet for up to $140 million, including an upfront payment and potential milestone payments. The iovera system uses cryoneurolysis for pain relief, particularly for knee osteoarthritis. Pacira plans to use the proceeds to strengthen its balance sheet and continues to focus on its non-opioid pain therapies and pipeline developments.
Pacira divests iovera device to Zimmer Biomet for up to $140m
Pacira BioSciences has announced the sale of its iovera pain relief device to Zimmer Biomet Holdings for up to $140 million. The deal includes an upfront payment of $70 million and potential milestone payments, with Pacira planning to use the net proceeds to strengthen its balance sheet. The iovera system uses cryoneurolysis for pain relief, particularly for knee osteoarthritis, and the transaction is expected to close in the third quarter of 2026.
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M
Pacira BioSciences (NASDAQ: PCRX) has agreed to sell its iovera° cryoanalgesia device business to Zimmer Biomet for a total consideration of up to $140 million. This includes an upfront payment of $70 million and up to an additional $70 million in revenue-based milestone payments through 2031, contingent on iovera° net revenue targets. The divestiture aligns with Pacira's strategy to focus on becoming an innovative biopharmaceutical company, with proceeds used to strengthen its balance sheet.
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences is divesting its iovera® business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million and potential future milestone payments. This move aligns with Pacira's "5x30 strategy" and supports its transition into an innovative biopharmaceutical company, while Zimmer Biomet aims to expand global access to the iovera° system. The companies will also collaborate on advancing the spasticity program.
Pacira offloads iovera° for up to $140M, keeps spasticity program
Pacira BioSciences announced the divestiture of its iovera° cryoneurolysis pain-treatment business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. The companies will also collaborate on a spasticity program, with potential additional compensation for Pacira upon the successful completion of a registrational study and regulatory approval. This transaction supports Pacira's strategy to transition into an innovative biopharmaceutical company and utilize the initial proceeds to pay down its senior secured revolving credit facility.
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences has announced an agreement to divest its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. This strategic move aligns with Pacira's 5x30 strategy and advances its transition into an innovative biopharmaceutical company, while Zimmer Biomet will gain the global rights, titles, and interests for iovera° development, manufacture, and commercialization. The companies will also collaborate on advancing a spasticity program, with Pacira potentially receiving additional compensation upon successful completion and regulatory approval.
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences has announced an agreement to divest its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million and potential future revenue-based milestone payments. This transaction supports Pacira's strategy to become an innovative biopharmaceutical company and will see both companies collaborate on advancing the spasticity program. Zimmer Biomet will gain all rights to iovera°, a drug-free medical device for pain relief, with the deal expected to close in Q3 2026.
Zimmer Biomet Refinances With New $1.5B Five-Year and $1.25B 364-Day Facilities; 2025 Lines Ended
Zimmer Biomet has refinanced its liquidity facilities by securing a new $1.5 billion five-year revolving credit agreement and a new $1.25 billion 364-day revolving credit agreement, both signed on June 26, 2026, with JPMorgan Chase Bank. Simultaneously, the company terminated its existing 2025 five-year and 364-day revolvers, incurring approximately $0.4 million in fees for the five-year facility. These new agreements will support general corporate purposes and enhance Zimmer Biomet's financial flexibility.
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors
Zimmer Biomet Holdings Inc. (ZBH) shares fell 2.00% on Monday, closing at $91.24, despite a generally positive trading session for the broader stock market. This decline broke a four-day winning streak for the company's stock. The S&P 500 Index rose 1.18%, and the Dow Jones Industrial Average gained 0.59%.
Zimmer Biomet (ZBH) secures new five-year and 364-day credit lines
Zimmer Biomet Holdings, Inc. (ZBH) has established two new unsecured revolving credit agreements: a five-year facility for $1.5 billion maturing in 2031 and a 364-day facility for $1.25 billion maturing in 2027, both for general corporate purposes. These new agreements replace terminated 2025 credit facilities, with all outstanding letters of credit transferred to the new five-year facility. The credit lines feature floating interest rates based on Term SOFR or an alternate base rate, plus a margin linked to the company's long-term debt rating, and include a leverage covenant.
Price to sales forward of Zimmer Biomet Holdings, Inc. – SWB:ZIM
This article provides financial data for Zimmer Biomet Holdings, Inc. (SWB:ZIM), specifically showcasing its "price to sales forward" metric. The content is presented by TradingView and includes various market data and reference information from providers like ICE Data Services and FactSet. It is primarily a data display page rather than a detailed news analysis.
Price to earnings forward of Zimmer Biomet Holdings, Inc. – SWB:ZIM
This article provides the "Price to earnings forward" for Zimmer Biomet Holdings, Inc. (SWB:ZIM) on the Stuttgart Stock Exchange. It indicates that the market was closed with no trades recorded at the time of publication. The content is presented as a financial data point from TradingView, with data sourced from ICE Data Services and FactSet.
Is Zimmer Biomet Holdings (ZBH) Undervalued After Raising Earnings Guidance?
Zimmer Biomet Holdings (ZBH) has reaffirmed its revenue growth outlook while raising earnings guidance, driven by a commercial overhaul and a focus on robotics. Despite recent share underperformance, the stock appears undervalued, trading at a P/E of 23.1x compared to industry and peer averages, and showing a significant discount based on a Discounted Cash Flow model. Investors are encouraged to assess the balance of potential risks and rewards, particularly given the long investment cycles in orthopedic robotics.
Enovis (ENOV) Could Be 46% Undervalued As Net Profit Jumps 84%
Enovis (ENOV) recently reported an 84.34% year-over-year increase in net profit on quarterly revenue of US$589.15 million, suggesting it could be significantly undervalued by 46% according to certain models, trading at US$22.71 against a fair value of US$42.30. Despite a weak year-to-date share price performance, the company's focus on next-generation technologies like Arvis and pipeline innovation in hips, knees, and shoulders positions it for potential growth, though risks from acquisitions and platform rollouts exist.
HeartFlow (NasdaqGS:HTFL) Stock Price
HeartFlow, Inc. (NasdaqGS:HTFL) has a market capitalization of US$3.1 billion and is currently trading at US$35.65, which is 3.6% undervalued compared to an analyst consensus target and fair value of US$37.00. The company's analysis highlights a strong balance sheet but concerning outlook, with recent news indicating its removal from the Russell 2000 Value Benchmark. HeartFlow specializes in non-invasive solutions for diagnosing coronary artery diseases using AI and computational fluid dynamics.
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains
Zimmer Biomet Holdings Inc. (ZBH) saw its stock rise by 2.35% on Friday, closing at $93.10, marking its fourth consecutive day of gains. However, despite this daily increase, the stock underperformed against the broader market, as the S&P 500 Index (SPX) fell 0.05% and the Dow Jones Industrial Average (DJIA) fell 0.09% on the same tough trading day.
